1[1]Boss V, Wang X, Koppelman LF, et aL Histamine induces nuclear factor of activated T cell-mediated transcription and cyclosporin A-sensitive interleukin-8 mRNA expression in human umbilical vein endothelial cells[J]. Mol Pharmacol, 1998, 54(2):264-272.
2[2]Kelly PA, Gruber SA, Behbod F, et al. Sirolimus, a new, potent immunosuppressive agent[J]. Pharmacotherapy, 1997, 17(6): 1148-1156.
3[3]Lauerma AI, Maibach HI, Granlund H, et al. Inhibition of contact allergy reactions by topical FK506[J]. Lancet, 1992, 340(8818): 556.
4[4]Mrowietz U. Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion[J]. Br J Dermatol, 1998, 139(6):992-996.
5[5]Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge[J]. Contact Dermatitis, 2000, 42(6): 349-350.
5BOSS V, WANG X, KOPPELMANI F, et al. Histamine induces nuclear factor of activated T cell-mediated transcription and cyclosporinesensitive interleulin-8 Mrna expression in human umbilical vein endothelial cell [ J]. Mol Pharmacol, 1998, 54 ( 2 ) :264 - 272.
6DUMONT F J. FK506 , an immunosuppressant targeting calcineurin function[J]. Curr Med Chem,2000,7(7) :731 -748.
7WOLLENBERG A, SHARMA S, VON BUBNOFF D,et al. Topical tacrolimus(FK506) leads to profound phenotypic and functional alterations of antigertpreseming dendritic cells in atopic dermatitis[ J]. ] Allergy Clin Immunoi ,2001,107 (3) :519 - 525.
8KOHYAMA T, TAKIZAWA H, KAWASAKI S, et al. A potent immunosuppressant FKS06 inhibits IL-8 expression in human eosinophils [J]. nol Cell Biol Res Commun, 1999,1 ( 1 ) :72 - 77.
9KELLY P A, GRUBER S A, BEHBOD F, et al. Sirolimus, a new, potent i mmunosuppressive agent [ J ]. Pharmacotherapy, 1997, 17 (6) : 1148 - 1156.
10NGHIEM P,PEARSON G,LANGLEY R G. Tacrolimus and pimecrolimus : From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis [ J]. J Am Acad Dermatol,2002 ,46 :228 - 241. 2004:20 : 191 - 199.
